The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiromichi Shirasu
No Relationships to Disclose
 
Jun Watanabe
Speakers' Bureau - Covidien; Johnson & Johnson/Janssen; Lilly Japan
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Keiji Hirata
No Relationships to Disclose
 
Naoya Akazawa
No Relationships to Disclose
 
Nobuhisa Matsuhashi
No Relationships to Disclose
 
Mitsuru Yokota
No Relationships to Disclose
 
Masataka Ikeda
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Pfizer; Taiho Oncology
Research Funding - Daiichi Sankyo (Inst)
 
Kentaro Kato
No Relationships to Disclose
 
Alexey Aleshin
Employment - Natera; Natera
Leadership - Natera
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Mission Bio; Mission Bio
Travel, Accommodations, Expenses - Natera
 
Shruti Sharma
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Research Funding - CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Syneos Health (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Ichiro Takemasa
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Yoshiaki Nakamura
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Masaki Mori
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)